Skopos Labs, Inc. Neurocrine Biosciences Inc Call Options Transaction History
Skopos Labs, Inc.
- $300 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
627Shares Held
94.3MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.82 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.28 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$659 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$329 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$238 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...